Robeco Institutional Asset Management B.V. Sells 83,084 Shares of Illumina, Inc. $ILMN

by · The Cerbat Gem

Robeco Institutional Asset Management B.V. lessened its holdings in Illumina, Inc. (NASDAQ:ILMN – Free Report) by 51.3% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 78,776 shares of the life sciences company’s stock after selling 83,084 shares during the period. Robeco Institutional Asset Management B.V. owned about 0.05% of Illumina worth $7,481,000 at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of ILMN. Bouvel Investment Partners LLC grew its holdings in shares of Illumina by 2.3% during the 3rd quarter. Bouvel Investment Partners LLC now owns 6,129 shares of the life sciences company’s stock valued at $582,000 after purchasing an additional 136 shares during the last quarter. Earned Wealth Advisors LLC boosted its position in Illumina by 13.9% in the third quarter. Earned Wealth Advisors LLC now owns 4,994 shares of the life sciences company’s stock valued at $474,000 after buying an additional 608 shares in the last quarter. Asset Management One Co. Ltd. grew its stake in shares of Illumina by 2.4% during the third quarter. Asset Management One Co. Ltd. now owns 113,551 shares of the life sciences company’s stock worth $10,784,000 after buying an additional 2,622 shares during the last quarter. Financiere des Professionnels Fonds d investissement inc. increased its holdings in shares of Illumina by 32.9% during the third quarter. Financiere des Professionnels Fonds d investissement inc. now owns 2,406 shares of the life sciences company’s stock worth $228,000 after buying an additional 596 shares in the last quarter. Finally, Signaturefd LLC increased its holdings in shares of Illumina by 3.7% during the third quarter. Signaturefd LLC now owns 4,918 shares of the life sciences company’s stock worth $467,000 after buying an additional 176 shares in the last quarter. Institutional investors and hedge funds own 89.42% of the company’s stock.

Illumina Stock Down 3.3%

Shares of NASDAQ:ILMN opened at $141.07 on Friday. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.12 and a current ratio of 1.43. Illumina, Inc. has a 52-week low of $68.70 and a 52-week high of $153.06. The business’s 50 day simple moving average is $130.01 and its two-hundred day simple moving average is $109.64. The firm has a market cap of $21.56 billion, a P/E ratio of 31.63, a PEG ratio of 2.43 and a beta of 1.41.

Illumina (NASDAQ:ILMN – Get Free Report) last issued its earnings results on Thursday, October 30th. The life sciences company reported $1.34 earnings per share for the quarter, topping analysts’ consensus estimates of $1.16 by $0.18. Illumina had a return on equity of 29.21% and a net margin of 16.40%.The company had revenue of $1.08 billion for the quarter, compared to analyst estimates of $1.07 billion. During the same period in the prior year, the firm earned $1.14 earnings per share. Illumina’s revenue for the quarter was up .4% on a year-over-year basis. Illumina has set its FY 2025 guidance at 4.650-4.750 EPS. As a group, research analysts forecast that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have recently commented on ILMN shares. Zacks Research lowered Illumina from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, December 31st. TD Cowen lifted their target price on shares of Illumina from $115.00 to $140.00 and gave the stock a “hold” rating in a research report on Wednesday. Evercore ISI restated an “outperform” rating and issued a $155.00 price target on shares of Illumina in a research report on Monday. Cowen reaffirmed a “hold” rating on shares of Illumina in a research note on Wednesday. Finally, Canaccord Genuity Group boosted their price objective on shares of Illumina from $112.00 to $130.00 and gave the stock a “hold” rating in a research note on Monday, December 22nd. Five investment analysts have rated the stock with a Buy rating, fourteen have assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $122.56.

Get Our Latest Report on Illumina

Insider Buying and Selling at Illumina

In other Illumina news, Director Scott Gottlieb bought 500 shares of the firm’s stock in a transaction dated Monday, November 3rd. The stock was bought at an average cost of $122.13 per share, with a total value of $61,065.00. Following the completion of the transaction, the director directly owned 12,523 shares in the company, valued at approximately $1,529,433.99. The trade was a 4.16% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Scott M. Davies sold 323 shares of the company’s stock in a transaction dated Friday, December 12th. The stock was sold at an average price of $136.09, for a total transaction of $43,957.07. Following the completion of the sale, the insider owned 17,887 shares in the company, valued at $2,434,241.83. This represents a 1.77% decrease in their position. The disclosure for this sale is available in the SEC filing. Corporate insiders own 2.60% of the company’s stock.

Illumina Profile

(Free Report)

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.

See Also